Oral Presentation Crystal36-AXAA Conference 2026

Warming up: serial crystallography in Australia (150685)

Nadia A Zatsepin 1
  1. Swinburne University of Technology, Hawthorn, VIC, Australia

Living systems are warm and dynamic, yet most crystal structures come from cryocooled crystals: convenient and dose-tolerant, but potentially misleading. Cryoprotectants and cryocooling can remodel side chains, bias conformational ensembles and hide functionally relevant states, with consequences for structure-based drug discovery [1].

In serial crystallography we determine structures by merging diffraction snapshots from many thousands of randomly oriented microcrystals, so each crystal receives only a fraction of the total dose and data can be collected at room temperature. X-ray free-electron lasers led this revolution, wherein we obtained room-temperature structures from microcrystals while outrunning (most) radiation damage, and molecular movie snapshots from nanosecond to femtosecond dynamics of light-activated proteins [2, 3] to enzyme intermediates captured after mixing [4]. Synchrotrons worldwide are now racing to make serial and time-resolved serial synchrotron crystallography (TR-SSX) broadly accessible.

We launched a method development Collaborative Access Program at MX3 in 2026. The first year yielded the first high-resolution room-temperature SSX structures from MX3 (lysozyme, thaumatin, and the antivirulence target DsbA, both apo and in complex with a drug candidate) using in-tray and bespoke fixed-target and microfluidic sample delivery, preliminary radiation damage investigations, data collection scripts and on-site high-throughput analysis with CrystFEL [5].

Turning this into an accessible technique poses new challenges: robust sample delivery for static and time-resolved experiments, accurate reaction initiation, large data volumes and complex analysis. We aim to extend SSX to nanocrystals using X-ray fluctuation scattering [6], to build and commission a tape drive for microcrystal delivery and TR-SSX [7], and to capture intermediate states of DsbA during inhibitor binding [8]. Our goal is to reach biomedical and chemical targets that resist conventional crystallography, to see drug targets flex to expose cryptic pockets, watch molecules bind, and catch enzymes mid-reaction at room temperature. In this talk I will present SSX, temperature effects, and our recent progress, while Chris Szeto and Alan Salek will present highlights from our collaboration in this session.

Where we are heading is multi-dimensional serial crystallography: structures resolved not only in time, but across temperature, pH, humidity and ligand binding. One day, “what is the structure of X?” will be answered not by a single “frozen” average, but by the fuller landscape of conformations a molecule visits as it carries out its function.

[1] Stachowski TR, Fischer M. Nat. Chem. Biol. 22, 169–179 (2026).
[2] Tenboer J, Basu S, Zatsepin N et al. Science 346, 1242–1246 (2014).
[3] Pande K, Hutchison CDM, Groenhof G et al. Science 352, 725–729 (2016).
[4] Olmos JL, Pandey S, Martin-Garcia JM et al. BMC Biol. 16, 59 (2018).
[5] White TA, Mariani V, Brehm W et al. J. Appl. Cryst. 49, 680–689 (2016).
[6] Adams P, Greaves TL, Martin AV. IUCrJ 11, 538–555 (2024).
[7] Zielinski KA, Prester A, Andaleeb H et al. IUCrJ 9, 778–791 (2022).
[8] Mohanty B, Alwan WS, Gunzburg MJ et al. Angew. Chem. Int. Ed. 64, e202515306 (2025).